Print this page    •   Back to Web version of article

U.S. News
Johnson & Johnson Unit Submits HIV Drug Candidate to FDA for Approval

July 20, 2007

On Wednesday, Johnson & Johnson's Tibotec Pharmaceuticals Ltd. division said it had filed a new application for Food and Drug Administration approval of TMC125 (etravirine), its new HIV drug candidate. FDA's decision to fast-track TMC125 means the company can submit data as it becomes available, rather than all at once. The treatment for people infected with HIV-1 is meant to be administered with other antiretrovirals.

Back to other news for July 2007

Excerpted from:
Associated Press

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.